STAAR SURGICAL CO

Staar Surgical’s modest 0.53 % rise is a warning sign—thin trading, price below its 200‑day average, and no disclosed earnings make the current valuation questionable. Click to learn why this eye‑care stock may be overhyped.

Staar Surgical climbs 4.07 % on Friday, 13.59 % month‑to‑date, as investors eye its high‑margin contact lenses, cataract devices and myopia‑control innovation.

Staar Surgical’s shares dip 3.18% to $21.61, below the 200‑day MA, amid valuation squeeze, limited diversification and shallow liquidity—investors should weigh risks carefully.

Staar Surgical (STAA) rises 2.01%, trading at $22.32 with a $1.1B market cap—discover the latest price action, peer performance, and its focus on high‑margin visual implants.